Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now early-phase tilt small index

Synovial Sarcoma: early-phase trial registry

7 of 12 indexed Synovial Sarcoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,429 of 28,707 conditions by registered trial count.

12 US clinical trials · 7 currently recruiting · #1,429 of 28,707 conditions by registered trial count

Synovial Sarcoma: 12 US clinical trials tracked, 7 recruiting.

Synovial Sarcoma is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is Uswm CT, running 2 of these trials.

Enrollment posture brief

Registry condition synovial-sarcoma

OPEN 7 | RECR 58% | LATE 1 | EARLY 10 | RANK #1429 | SPON 2

Nearest open-share peer: Anterior Cruciate Ligament Reconstruction (58% recruiting · 12 trials)

Synovial Sarcoma (this)58%Acute Myeloid Leukemia in Re41.7%Adenocarcinoma of the Rectum41.7%Adherence, Patient16.7%Accelerated Phase Chronic My0%
Open-enrollment share among volume-matched conditions near Synovial Sarcoma

Synovial Sarcoma lists 7 open slots (58% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Synovial Sarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Synovial Sarcoma is recruiting above its size-band peers.

    7 of 12 indexed trials (58.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Synovial Sarcoma research.

    Uswm CT accounts for 2 of 12 trials (16.7%). 11 distinct sponsors appear on at least one study for this condition label.

  3. Most Synovial Sarcoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 44 among the 12 trials that report a genuine target (sentinel values excluded). 9 of those (75%) plan for fewer than 100 participants.

  4. Synovial Sarcoma research is mostly interventional.

    11 interventional and 1 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 18Phase 22Phase 31

Open and recent trials

12 total, page 1 of 1

RECRUITING 1,000 participants

Synovial Sarcoma Registry / Biospecimen Repository

Children's Hospital of Philadelphia

NCT05910307

RECRUITING Phase 3 325 participants

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

Advenchen Laboratories

NCT03016819

RECRUITING Phase 1 44 participants

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

M.D. Anderson Cancer Center

NCT06083883

RECRUITING Phase 1 27 participants

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

University of Florida

NCT06625190

RECRUITING Phase 1 25 participants

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Baylor College of Medicine

NCT04995003

RECRUITING Phase 1 20 participants

SPEARHEAD-3 Pediatric Study

Uswm CT

NCT05642455

RECRUITING Phase 1 15 participants

ACTengine® IMA203 Combined With mRNA-4203

Immatics US

NCT06946225

ACTIVE NOT RECRUITING Phase 1 71 participants

MAGE-A4ᶜ¹º³²T for Multi-Tumor

Adaptimmune

NCT03132922

ACTIVE NOT RECRUITING Phase 2 52 participants

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Uswm CT

NCT04044768

COMPLETED Phase 1 109 participants

EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Epizyme

NCT02601937

COMPLETED Phase 2 20 participants

Bevacizumab and Radiation Therapy for Sarcomas

Massachusetts General Hospital

NCT00356031

COMPLETED Phase 1 19 participants

Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma

University of Louisville

NCT01241162

Phase Distribution

PhaseTrial count
Phase 1 8
Phase 2 2
Phase 3 1

Named interventions

Most-linked intervention names on Synovial Sarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Autologous dendritic cell vaccine with adjuvant Biological
1 trials
afamitresgene autoleucel (previously ADP-A2M4) Genetic
1 trials
Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation Radiation
1 trials
Autologous genetically modified MAGE-A4ᶜ¹º³²T cells Genetic
1 trials
Digoxin (0.25mg) Drug
1 trials
Midazolam 2 mg for CYP3A4 phenotyping Drug
1 trials
AL3818 or placebo Drug
1 trials
AL3818 Drug
1 trials

US sites by state

Facility locations filed on Synovial Sarcoma trials. A trial with sites in several states counts in each.

Texas 7 trials
New York 6 trials
Pennsylvania 5 trials
Massachusetts 5 trials
California 5 trials
Washington 4 trials
Tennessee 4 trials
Ohio 4 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Synovial Sarcoma page

12 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 7 Synovial Sarcoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Uswm CT sponsors the most Synovial Sarcoma trials on record, review their full trial history before evaluating a specific study. See Uswm CT's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Synovial Sarcoma condition card totals 12 registered trials; most-linked intervention Autologous dendritic cell vaccine with adjuvant; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.